Logo
x

Search

Subscribe Now

opdivo

PharmaShots Interview: BMS' Dr. Ian Waxman Shares Insights on the Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC

PharmaShots Interview: BMS' Dr. Ian Waxman Shares Insights on the Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC

  • September 28, 2021
Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metast...

  • August 25, 2021
BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

  • August 23, 2021
BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell Carcinoma

BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell...

  • August 17, 2021
BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcino...

  • March 1, 2021
BMS Report Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable Non-Small Cell Lung Cancer

BMS Report Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable Non-Small Cell Lung Cancer

  • October 8, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.